干粉吸入器市场（2026—2031）
干粉吸入器市场规模预计由2026年的256.4亿美元增至2031年的327.1亿美元，预测期复合年增长率为4.97%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
干粉吸入器市场规模预计由2026年的256.4亿美元增至2031年的327.1亿美元，预测期复合年增长率为4.97%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 4.97% | 机构预测 |
| 市场规模 | 2026 | USD 25.64 billion | 机构预测 |
| 市场规模 | 2031 | USD 32.71 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| device_lifecycle | reusable inhalers | 2025 | 58.110% |
| distribution_channel | retail pharmacies | 2025 | 47.410% |
| drug_class | inhaled corticosteroid combination therapies | 2025 | 42.160% |
| geography | North America | 2025 | 38.110% |
| indication | asthma | 2025 | 52.160% |
| product_type | blister-based devices | 2025 | 36.180% |
关键结论
- device_lifecycle 维度中，reusable inhalers 在 2025 年的公开份额为 58.11%。
- distribution_channel 维度中，retail pharmacies 在 2025 年的公开份额为 47.41%。
- drug_class 维度中，inhaled corticosteroid combination therapies 在 2025 年的公开份额为 42.16%。
- geography 维度中，North America 在 2025 年的公开份额为 38.11%。
- indication 维度中，asthma 在 2025 年的公开份额为 52.16%。
- product_type 维度中，blister-based devices 在 2025 年的公开份额为 36.18%。
主要参与者
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Novartis AG
- Teva Pharmaceutical Industries Limited
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Asthma, COPD, and Cystic Fibrosis Burden | +1.300% | Global | Long term (≥ 4 years) |
| Preference for Propellant-Free Pulmonary Delivery | +1.000% | Global, with early gains in Europe and North America | Medium term (2-4 years) |
| Expansion of Home-Based Respiratory Care | +0.700% | North America, Europe, and core Asia-Pacific markets | Medium term (2-4 years) |
| Growth of High-Payload and Inhaled Biologic Programs | +0.600% | North America, Europe, Asia-Pacific, and spillover to the Middle East and Africa | Long term (≥ 4 years) |
| Digital Adherence Monitoring in Chronic Respiratory Therapy | +0.400% | North America and Europe, with early gains in Asia-Pacific | Medium term (2-4 years) |
| Localized Device-Formulation Optimization for Low-Flow Patients | +0.300% | Global, with early gains in Asia-Pacific and the Middle East and Africa | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Patient Inspiratory-Flow Limitations | -0.700% | Global, with greater effect in Asia-Pacific and the Middle East and Africa | Long term (≥ 4 years) |
| Complex Drug-Device Bioequivalence Requirements | -0.500% | North America and Europe | Long term (≥ 4 years) |
| Moisture Sensitivity and Powder Stability | -0.400% | Asia-Pacific, the Middle East and Africa, and South America | Medium term (2-4 years) |
| Fragmented Digital-Device Data and Privacy Standards | -0.300% | Global, with acute effects in Europe and North America | Short term (≤ 2 years) |
报告关注的关键问题
What is the projected value of dry powder inhalers by 2031?
The dry powder inhalers market is projected to reach USD 32.71 billion by 2031, from USD 25.64 billion in 2026. The forecast represents a 4.97% CAGR for 2026 to 2031. It reflects continued use of maintenance treatment and the expanding role of propellant-free delivery options.
What is driving demand for dry powder inhalers?
Chronic respiratory disease, propellant-free delivery, home-based care, and complex inhaled formulations support demand. Clinical evidence also supports device selection based on patient needs because dry powder inhalers and pressurized metered-dose inhalers showed comparable efficacy and safety in the cited 2026 review.
Which dry powder inhaler product type leads revenue?
Blister-based devices led product-type revenue with a 36.18% share in 2025. Their position is supported by precise dose metering, established manufacturing capability, and broad compatibility with several types of respiratory formulation. Multi-dose blister formats also fit fixed-dose combination treatment.
Which distribution channel is growing fastest for dry powder inhalers?
Online pharmacies are forecast to grow at a 7.02% CAGR through 2031, supported by e-prescriptions and adherence services. Provider-led programs that combine electronic inhaler monitoring with remote support improved adherence in the cited 2024 review.
Which region has the fastest projected growth?
Asia-Pacific is forecast to grow at a 6.93% CAGR through 2031, the fastest regional rate in the supplied data. Reimbursement expansion in China and growing treatment access across other Asian countries support this outlook.
Why do some patients struggle with dry powder inhalers?
Some older patients and people with advanced COPD cannot reliably generate the inspiratory flow needed for consistent powder delivery. Clinicians may need to assess inhalation ability, provide training, and consider a different device where the patient cannot achieve adequate flow. This remains an important limitation for the most severe COPD population.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence